Related Experiment Video
Updated: Oct 26, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androprostamine A: a unique antiprostate cancer agent
Yohko Yamazaki1, Hikaru Abe2, Chiharu Sakashita2
1Institute of Microbial Chemistry (BIKAKEN), Numazu Branch, Numazu, Shizuoka, 410-0301, Japan. yamako@bikaken.or.jp.
Researchers discovered androprostamine A (APA), a compound from microorganisms, that inhibits prostate cancer cell growth by targeting the androgen receptor (AR). An APA derivative also showed significant tumor reduction in mice.
Area of Science:
- Microbiology
- Oncology
- Molecular Biology
Background:
- The androgen receptor (AR) is a key therapeutic target in prostate cancer treatment.
- Developing novel AR-targeting agents is crucial for managing all stages of prostate cancer.
- Identifying compounds from natural sources offers a promising avenue for new cancer therapies.
Purpose of the Study:
- To screen microbial culture broths for compounds that inhibit androgen-dependent prostate cancer cell growth.
- To identify and characterize novel inhibitors of the androgen receptor pathway.
- To evaluate the therapeutic potential of identified compounds and their derivatives in preclinical models.
Main Methods:
- Screening of microbial culture broths for cytotoxic and anti-proliferative effects on LNCaP and VCaP prostate cancer cells.
- Characterization of androprostamine A (APA) as a functional inhibitor of the androgen receptor.
- Assessment of APA's effect on androgen-regulated gene expression and prostate-specific antigen (PSA) levels.
- Evaluation of an APA derivative (AS2405) for in vivo efficacy in a mouse xenograft model.
Main Results:
- Androprostamine A (APA) was identified from a Streptomyces culture broth as a suppressor of androgen-dependent prostate cancer cell growth.
- APA repressed R1881-induced androgen-regulated gene expression and prostate-specific antigen (PSA) levels without direct AR antagonism or inhibition of transcriptional activity.
- The APA derivative, AS2405, demonstrated significant inhibition of VCaP cell tumor growth in SCID mice following oral administration.
Conclusions:
- Androprostamine A (APA) represents a novel class of androgen receptor pathway modulators with potential therapeutic applications in prostate cancer.
- APA's mechanism of action, distinct from direct AR antagonism, warrants further investigation.
- The in vivo efficacy of AS2405 supports the development of APA derivatives as orally bioavailable agents for prostate cancer treatment.
More Related Videos
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
08:38Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...